Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 4NET 2Head & Neck 1

Conditions

Neuroendocrine Tumors 12Gastro-enteropancreatic neuroendocrine tumor 4Carcinoid Tumor 3Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Pancreatic Neuroendocrine Tumor G2 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Acromegaly 1

Interventions

Octreotide 2motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1Sorafenib 1Oxaliplatin 1Leucovorin 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Everolimus 1Cytokines 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × Octreotide × NET × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡